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Abstract: Injectable nanoscale hydroxyapatite (nHA) systems are highly promising biomaterials to
address clinical needs in bone tissue regeneration, due to their excellent biocompatibility, bioinspired
nature, and ability to be delivered in a minimally invasive manner. Bulk strontium-substituted
hydroxyapatite (SrHA) is reported to encourage bone tissue growth by stimulating bone deposition
and reducing bone resorption, but there are no detailed reports describing the preparation of a
systematic substitution up to 100% at the nanoscale. The aim of this work was therefore to fabricate
systematic series (0–100 atomic% Sr) of SrHA pastes and gels using two different rapid-mixing
methodological approaches, wet precipitation and sol-gel. The full range of nanoscale SrHA materials
were successfully prepared using both methods, with a measured substitution very close to the
calculated amounts. As anticipated, the SrHA samples showed increased radiopacity, a beneficial
property to aid in vivo or clinical monitoring of the material in situ over time. For indirect methods,
the greatest cell viabilities were observed for the 100% substituted SrHA paste and gel, while direct
viability results were most likely influenced by material disaggregation in the tissue culture media. It
was concluded that nanoscale SrHAs were superior biomaterials for applications in bone surgery,
due to increased radiopacity and improved biocompatibility.
Keywords: nanoscale calcium phosphate; strontium; injectable biomaterial; bone graft substitute
1. Introduction
Annually, millions of patients worldwide require grafts or alloplastic biomaterials to
repair bone defects caused by trauma, cancer surgery, or congenital deformities. When bone
healing is compromised, there can be a great detrimental impact on a patient’s quality of life
as well as increased treatment costs. The current gold standard material is an autologous
bone graft typically taken from the iliac crest of the patient. However, harvesting of the
bone has significant disadvantages in terms of donor-site morbidity, pain suffered by the
patient, and graft availability. Bone allograft is therefore commonly employed, but this has
associated risks, including viral or prion transmission and a less predictable host response
due to processing [1]. Therefore, there is a great interest in improved synthetic biomaterials
for effective and consistent bone tissue regeneration. The ideal bone augmentation material
should be osteoconductive to aid the regrowth of bone tissue, and be available in a suitable
form to allow for the surgeon to easily implant it into the defect site.
Synthetic calcium phosphates, such as hydroxyapatite (HA), have been widely used
in medicine and dentistry. Nanoscale hydroxyapatite (nHA) can be considered bioinspired
due to its similarity to the mineral found naturally in bone and tooth enamel [2,3]. Calcium
phosphates have typically been used in the form of powders, granules, or as coatings
on the surface of implants. However, the development of nHA has allowed alternative
forms of bone graft substitute to be investigated. One promising technology that has been
developed is a paste based upon the combination of nHA with water. Clinical and animal
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data for the first generation of nanoscale calcium phosphate paste products (including
NANOSTIM (Medtronic) and ReproBone® novo (Ceramisys Ltd. Sheffield, UK)) are en-
couraging, suggesting that they are capable of promoting bone tissue regeneration [4,5].
The reasons underpinning their good clinical performance may be due, in part, to the
extremely high surface area-to-volume ratio and bioinspired use of nanoscale calcium
phosphates. In detail, it has been suggested that bioinspired elements, such as nanoscale
dimensions, calcium deficiency and carbonate substitution [6], may also contribute to a
more favourable biological response [2,7]. Advantageously, these systems are injectable,
thereby facilitating minimally invasive surgeries, and nanoscale calcium phosphates may
be chemically modified to enhance their clinical performance. Despite this potential,
modified nanoscale calcium phosphates have had little impact on the market, or clini-
cally. There is also a lack of laboratory studies that have considered the substitution of
other chemical elements into injectable nanoscale calcium phosphate systems. Strontium-
substituted hydroxyapatite (SrHA) is of particular interest, due to its ability to enhance
bone regeneration through the stimulation of osteoblasts, inhibition of osteoclasts [8], and
encouragement of mesenchymal stromal cell osteogenic differentiation [9]. Furthermore,
it has been shown that the presence of strontium-substituted biphasic calcium phosphate
decreased pro-inflammatory cytokine production, suggesting that Sr may assist in control-
ling inflammatory processes [10]. Recent studies regarding injectable SrHA cement [11]
and SrHA integrated with phosphoserine-tethered poly(epsilon-lysine) dendrons [12] have
suggested that these materials are promising candidates for bone regeneration purposes,
but neither of these studies investigated the full range of possible Sr substitution (i.e., up to
100 at.% Sr).
Sr can substitute into the hydroxyapatite crystal structure in the place of Ca, which
causes a linear expansion of the lattice constants [6]. The resulting biological effects may be
due to the presence of Sr distorting the crystal lattice, which contributes to a greater solubil-
ity for increasing Sr concentrations when compared to Ca hydroxyapatite [13]. The majority
of published reports have only investigated limited levels of Sr incorporation [8,9,14,15].
Alternatively, the following reports have investigated the material properties of SrHA pro-
duced over the whole range of possible substitution levels, but without characterising their
biological effects [16,17]. Whilst there have been some reports describing the biological
effects of SrHA over a range of Sr compositions, to date these relied on production via a
single synthesis route [18,19].
Due to the different Sr ranges investigated and the different methods used to prepare
the materials, it is impossible to fully appreciate the effect of the synthesis route on the ma-
terials produced and their biocompatibility. By investigating only one production method,
it can be difficult to conclude whether a Sr concentration is optimal, or if production effects
and the final form of the material are also responsible for differences in the biological effects
observed. Similarly, there are very limited reports on injectable SrHA systems. For instance,
Raucci et al. investigated SrHA gels, but only up to 20 atomic (at.)% Sr incorporation [9].
Other early reports have also focussed on low levels of Sr incorporation into SrHA [8,20,21].
Since the solubility of SrHA increases with higher Sr amounts [13], investigations into
higher Sr concentrations, e.g., 50 and 100 at.% SrHA, may more clearly demonstrate how
differences in solubility affect not only the properties of the biomaterial system, but also
the preparation of these materials. There is clear evidence in the literature that different
methods of nanoscale hydroxyapatite production can have a significant effect on the chem-
ical and physical properties [22]. Therefore, there is a need for investigations that report
the production and comparison of SrHA manufactured using alternative synthesis routes
to produce consistent materials in a form suitable for delivery via a minimally invasive
method, such as injection.
A variety of methods are available to produce biomimetic nanoscale hydroxyapatite,
including hydrothermal and wet precipitation [22–24]. Advantageously, wet precipitation
methods do not require specialised equipment to achieve high pressures and temperatures
associated with the hydrothermal method. The authors have previously reported a rapid-
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mixing wet precipitation method [24] for the preparation of nanoscale hydroxyapatite. This
method has also been used to prepare silver-doped nanoscale hydroxyapatite pastes with
antibacterial properties [25], thereby demonstrating its versatility for the preparation of
chemically modified materials. It has not, however, yet been evaluated for the fabrication
of novel injectable SrHA pastes or gels. The aim of this study was therefore to fabricate
systematic series (0, 2.5, 5, 10, 50, and 100 atomic% Sr) of SrHA pastes and gels using two
different methodological approaches, wet precipitation and sol-gel, and fully characterise
the different products. On completion of this research, a reliable method for the preparation
of consistent SrHAs will have been identified, suitable for adoption by the medical devices
or related biopharma industry.
2. Materials and Methods
All reagents were obtained from Sigma-Aldrich (Gillingham, UK) unless otherwise stated.
2.1. Strontium-Substituted Nanoscale Hydroxyapatite (SrHA) Paste Preparation Using
Rapid-Mixing Wet Precipitation
A rapid-mixing method to prepare nanoscale calcium hydroxyapatite previously
published by the authors [24] was modified to prepare a range of strontium-substituted
nanoscale hydroxyapatite (SrHA: 0, 2.5, 5, 10, 50 and 100 at.% Sr). Specifically, the appro-
priate amount of calcium hydroxide (Ca(OH)2, ≥96% purity) was added alongside the
appropriate amount of strontium hydroxide octahydrate (Sr(OH)2·8H2O, 95% purity) to
500 mL deionised water (Table 1). The calcium/strontium hydroxide suspension was then
stirred for 1 h at 400 rpm.
Table 1. Reagent amounts used to produce SrHA (0, 2.5, 5, 10, 50 and 100 at.% Sr) using rapid-mixing wet precipitation
method. Strontium incorporation and (Ca + Sr)/P molar ratio achieved, characterised using X-ray fluorescence.






g mmol G mmol Sr / (Sr + Ca) at.% (Ca + Sr)/P Molar Ratio
0 3.70 50 0 0 0.02 1.63
2.5 3.61 48.75 0.33 1.25 2.45 1.57
5 3.52 47.5 0.66 2.5 4.83 1.57
10 3.33 45 1.33 5 9.55 1.56
50 1.85 25 6.64 25 49.67 1.58
100 0 0 13.29 50 99.79 1.50
A phosphoric acid solution (H3PO4, 30 mmol phosphoric acid (85 wt.% in water,
99.99% purity) dissolved in 250 mL deionised water) was poured into the calcium/strontium
hydroxide suspension and the suspension was stirred for a further 1 h. The suspensions
were left to settle for approximately 20 h. The SrHA suspensions were then washed at least
three times with 500 mL deionised water. Additional washes were carried out until the
conductivity was below 15 µS·cm−1, measured using FG3 FiveGo™ portable conductiv-
ity meter (Mettler Toledo™, Leicester, UK). However, washing was discontinued if the
conductivity did not decrease by 10 µS·cm−1 with 4 subsequent washes.
In order to produce a powder for materials characterisation the SrHA suspensions
were dried at 60 ◦C in a drying oven and ground in an agate mortar and pestle. Half of the
powder sample was sintered in order to investigate the thermal stability of the materials.
The ground powder was placed in a furnace (UAF 15/5, Lenton) with a ramp rate of
10 ◦C·min−1 to a temperature of 1000 ◦C, which was maintained for 2 h.
In order to prepare a paste for biocompatibility testing the SrHA suspensions were
dried at 60 ◦C in an oven until the paste had a water content of 80 wt.%. This water content
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was selected due to the formation of a stable paste suspension that had good injectable
properties when loaded into a syringe. The pastes were then stored in sealed universal
tubes, sterilised using 25 kGy gamma irradiation from a cobalt 60 source (Swann-Morton
Ltd., Sheffield, UK) and loaded into 1 mL syringes prior to use.
2.2. Strontium-Substituted Nanoscale Hydroxyapatite Gel Preparation Using Rapid-Mixing
Sol-Gel Method
SrHA gels (0, 2.5, 5, 10, 50 and 100 at.% Sr) were prepared using a rapid-mixing sol-gel
method. Briefly, the appropriate amount of calcium nitrate tetrahydrate (Ca(NO3)2·4H2O, >99%
purity) was dissolved alongside the appropriate amount of strontium nitrate (Sr(NO3)2, >99%
purity) in 500 mL deionised water (Table 2). Ammonium phosphate dibasic ((NH4)2HPO4,
≥98% purity, 3.96 g (30 mmol)) was dissolved in 250 mL deionised water. The pH of the
calcium/strontium nitrate solution and the ammonium phosphate solutions were then
adjusted to 11 and 12, respectively, using 1 M potassium hydroxide (KOH, >85% pu-
rity) solution. This was measured using the pH 211 microprocessor pH meter (Hanna
Instruments). The phosphorus solution was poured into the calcium/strontium solution,
which was then stirred for 1 h at 400 rpm and the SrHA suspension was left to settle
for approximately 20 h. The SrHA suspensions were then washed and dried using the
same parameters as described for the wet precipitation method above. Due to excessive
thermal decomposition at 1000 ◦C, 0 and 100 at.% SrHA were sintered at 700 ◦C for 2 h
using the same parameters as described for the wet precipitation method above, in order
to investigate their thermal stability.
Table 2. Reagent amounts used to produce SrHA (0, 2.5, 5, 10, 50 and 100 at.% Sr) using rapid-mixing sol-gel method.
Strontium incorporation and (Ca + Sr)/P molar ratio achieved, characterised using X-ray fluorescence.






g mmol g mmol Sr/(Sr + Ca) at% (Ca + Sr)/P Molar Ratio
0 11.81 50 0 0 0.01 1.59
2.5 11.51 48.75 0.26 1.25 2.32 1.56
5 11.22 47.5 0.53 2.5 4.81 1.50
10 10.63 45 1.06 5 9.01 1.54
50 5.90 25 5.29 25 45.11 1.48
100 0 0 10.58 50 99.91 1.52
SrHA gels of 90 wt.% water content were prepared as this method allowed for the
formation of a stable gel-like suspension with a higher water content (90 wt.%) than the
suspensions formed by the rapid-mixing wet precipitation method. This allowed for the
comparison of injectable SrHA materials with different water contents. The gels were
stored and sterilised in the same manner as described for the SrHA pastes.
2.3. Material Characterisation
2.3.1. X-ray Diffraction (XRD)
SrHA powder samples were prepared for XRD by mixing with a small amount of
PVA glue on an acetate film, and dried using a hot air gun. Qualitative phase analysis was
performed on powdered samples using X-ray diffraction (STOE IP, Darmstadt, Germany)
with Cu Kα1 radiation, λ = 0.15406 nm. The diffractometer was operated at 40 kV and
35 mA, with a 2θ range of 20◦–60◦. The resulting patterns were analysed using ICDD
PDF 4+ software, with the following ICDD cards used for phase identification: 9-432—
calcium hydroxyapatite, 04-016-2959—2.4 at.% SrHA, 04-016-3585—5 at.% SrHA, 60-0648—
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10 at.% SrHA, 34-479—50 at.% SrHA, 33-1348—100 at.% SrHA, 04-014-2292—β-tricalcium
phosphate (β-TCP), 24-1008—β-tristrontium phosphate (β-TSP).
2.3.2. Transmission Electron Microscopy (TEM)
Powder samples were placed in ethanol and dispersed using ultrasound for 15 min,
before being pipetted onto a 400-mesh copper grid coated with a holey thin carbon film
(Agar Scientific, Stansted, UK). Electron microscopy was carried out in the Faculty of
Science, Department of MBB, The University of Sheffield. Morphological evaluation of the
SrHA particles was carried out using the Tecnai G2 Spirit TEM (FEI, Hillsboro, USA) at an
accelerating voltage of 80 kV. In order to obtain aspect ratios for the particles produced, the
lengths and widths of 10 particles were measured per sample.
2.3.3. X-ray Fluorescence (XRF)
SrHA powder (0.8 g) was combined with 8 g of lithium tetraborate (ICPH, Malzéville,
France). This mixture was melted into a glass disc in a furnace at 1200 ◦C. The glass discs
were analysed in an XRF spectrometer (PW2440, Philips, Eindhoven, The Netherlands) to
determine the elemental composition of the samples.
2.3.4. Fourier Transform Infrared Spectroscopy in Attenuated Total Reflectance Mode
(FTIR-ATR)
Thirty-two scans were performed on powder samples from 4000 to 500 cm−1 with a
resolution of 4 cm−1 (Thermo Scientific Nikolet Spectrometer, Unicam Ltd., Ilminster, UK).
Sixty-four background scans were initially taken with an empty set up and this scan was
then subtracted from all subsequent scans.
2.3.5. Radiopacity
SrHA powder (0.1 g) was placed in a 96-well plate in triplicate for each sample
produced. An X-ray image was taken with 0.25 s exposure time and developed in a dark
room alongside an aluminium step wedge in order to express the radiodensity of the
materials in mm of aluminium. The films were scanned and analysed using Quantity One
software to obtain quantitative values for the radiopacity of the materials.
2.4. In Vitro Biocompatibility of SrHA Pastes and Gels
MG63 human osteosarcoma cell line was cultured in T75 flasks in the following
media (v/v%): 87% minimum essential media Eagle’s α-modification (α-MEM), 10% foetal
calf serum (FCS, Labtech International Ltd., Heathfield, UK), 1% penicillin–streptomycin,
1% L-glutamine and 1% non-essential amino acids. When 70–80% confluent, the flasks
were washed twice with 10 mL phosphate buffered saline (PBS) used each time. Trypsin-
EDTA (2 mL) was added and the flasks were incubated for 5 min at 37 ◦C, 5% CO2. The
detachment of the cells from the flasks was monitored using light microscopy (Eclipse
TS100, Nikon, Tokyo, Japan). When the cells were detached, 4 mL FCS was added to
neutralise the trypsin. The cell suspension was placed in a tube and centrifuged for 5 min
at 1000 rpm. The supernatant was carefully removed and the cell pellet was resuspended
in an appropriate amount of media for cell counting using a haemocytometer. The cells
were then seeded for experiments or seeded for further culture in T75 flasks.
The protocols for direct and indirect biocompatibility were based on the ISO 10993-5
biocompatibility testing standard where appropriate [26]. The protocol for indirect bio-
compatibility was also advised by an internal communication from the IMCOSS project
(FP7-SME-315679).
2.4.1. Direct Biocompatibility of SrHA Pastes and Gels
For direct biocompatibility assays, 0.1 mL of paste or gel (0, 2.5, 5, 10, 50, and 100 at.%
Sr) was placed into a 24-well plate in triplicate. Direct cellular viability was also tested
for ReproBone® novo (Ceramisys Ltd., Sheffield, UK) using the same protocol alongside
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the paste or gel samples. A 1 mL cell suspension containing 50,000 MG63 cells was then
added to each well alongside control wells containing no material. Paste/gel wells with no
cells present were also prepared to act as material controls. The 24-well plates were then
incubated for 48 h at 37 ◦C, 5% CO2. After 48 h, light microscopy (Eclipse TS100, Nikon)
was used to image cells growing alongside the paste/gel materials. Cellular viability was
then tested using a PrestoBlue® assay. To prevent the disruption and loss of paste or gel
from the wells, 100 µL PrestoBlue® reagent (Fisher Scientific, Loughborough, UK) was
directly added to the wells, after 100 µL media had been removed. After 1 h, 200 µL of
the solution was transferred to a 96-well plate. The fluorescence of the samples was read
on a fluorescent plate reader (Infinite M200, Tecan, Reading, UK) with 535 nm excitation
and 590 nm emission wavelengths used. After the PrestoBlue® assay the wells were
washed twice with 1 mL PBS, and 400 µL of live/dead stain, prepared according to the
manufacturer’s instructions, was added to each well and incubated for 15 min at 37 ◦C,
5% CO2. The wells were then washed with PBS before being imaged using a fluorescence
microscope (Axiovert 200M, Zeiss, Cambridge, UK). Dead cells could not be imaged for the
direct biocompatibility assay due to red background fluorescence from residual PrestoBlue®
media solution, which had absorbed into the pastes and gels. The experiment was repeated
three times. All PrestoBlue® assays results were expressed as the mean of the three triplicate
repeats (n = 9). The results were tested for statistical significance using a one-way ANOVA
test with Tukey’s multiple comparisons test applied using GraphPad Prism 6 software.
2.4.2. Indirect Biocompatibility of SrHA Pastes and Gels
Indirect biocompatibility was investigated by incubating 0.5 mL of SrHA paste/gel
material (0, 2.5, 5, 10, 50 and 100 at.% Sr) with 5 mL media for 24 h at 37 ◦C to produce
pre-conditioned media. Pre-conditioned media for a commercially available nHA paste
(ReproBone® novo, Ceramisys Ltd.) was prepared following the same procedure, and 5 mL
of media was also incubated without any material present for a non-material control. At
the same time, 50,000 MG-63 human osteoblast-like cells in 1 mL media were seeded in a
24-well plate in triplicate for each sample and incubated for 24 h. After 24 h incubation,
the pre-conditioned media was centrifuged at 1000 rpm for 5 min. The media on the cells
was replaced by 1 mL pre-conditioned media and the cells were incubated again for 24 h.
Light microscopy was conducted in the same manner as described above to assess the
morphology of the cells cultured in the pre-conditioned medium. A PrestoBlue® assay was
carried out by removing the pre-conditioned media and adding 1 mL 10 v/v% dilution of
the PrestoBlue® in complete media to each well, with the assay, live/dead staining and
statistical analysis conducted in the same manner as described above. The experiment was
repeated three times, with the statistical analysis performed using a one-way ANOVA as




The addition of Sr caused a peak shift to lower degrees 2θ in the XRD patterns for the
apatite phases produced when greater amounts of Sr were used for both the rapid-mixing
wet precipitation and sol-gel methods (Figure 1). This peak shift to lower degrees 2θ
was also observed for the minor phase of Sr-substituted β-tricalcium phosphate that was
present for the apatite produced using the wet precipitation method after high-temperature
treatment (Figure 1B). High thermal stability was observed for the samples prepared using
the wet precipitation method, i.e., low amounts of decomposition of the hydroxyapatite into
β-tricalcium phosphate / β-tristrontium phosphate. However, the Sr-substituted samples
prepared using the sol-gel method displayed decomposition, which was in contrast to the
Ca nHA prepared using this method (Figure 1D). Therefore, there was no single sintering
temperature that could be employed to increase the sharpness of the diffraction peaks of
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Figure 1. XRD patterns of SrHA powders (0, 2.5, 5, 10, 50 and 100 at.% Sr) produced using wet precipitation (A,B) and













3.1.2. Transmission Electron Microscopy
Particles of 100 at.% SrHA, produced using both methods, had a noticeably larger
aspect ratio than any other level of Sr substitution (Figures 2 and 3). The samples were
generally homogenous particles, with smaller rounded particles observed for 0 at.% Sr
particles compared to elongated particles obtained at 100 at.% Sr. For the wet precipitation
method, the aspect ratio increased from 1.7 for 0 at.% Sr to 4.5 for 100 at.% Sr. In detail, the
average particle size increased from 50 × 30 nm for 0 at.% Sr to 90 × 20 nm for 100 at.% Sr.
The increase in the aspect ratio for the particles produced using the sol-gel method was
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even more pronounced, increasing from 2.5 for 0 at.% Sr to 6 for 100 at.% Sr. Specifically,
for the sol-gel method, the average particle size increased from 50 × 20 nm for 0 at.% Sr
to 120 × 20 nm for 100 at.% Sr. For the wet precipitation method, the particles produced
with 2.5, 5, 10 and 50 at.% Sr appeared to be composed of smaller particles, which were
agglomerated together. This was in contrast to the particles produced at 0 and 100 at.% Sr,
which had well-defined edges.
Figure 2. TEM micrographs of unsintered SrHA powders (0, 2.5, 5, 10, 50 and 100 at.% Sr) produced using the wet
precipitation method.
 
− ν − ν − − ν −
δ − − ν
−







Figure 3. TEM micrographs of unsintered SrHA powders (0, 2.5, 5, 10, 50 and 100 at.% Sr) produced using the sol-gel method.
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3.1.3. X-ray Fluorescence
XRF data showed the successful incorporation of Sr into the product, with the product
Sr/(Sr + Ca) close to the intended substitution level (Tables 1 and 2). However, the
(Ca + Sr)/P ratios were lower than the stoichiometric value (1.67). For each method, the
sample composed of Ca HA had the (Ca + Sr)/P ratio closest to the stoichiometric value
(1.63 and 1.59 for the wet precipitation and sol-gel methods, respectively). The samples
containing Sr had (Ca + Sr)/P ratios lower than these values.
3.1.4. Fourier Transform Infrared Spectroscopy in Attenuated Total Reflectance Mode
The FTIR-ATR spectra (Figure 4) for the range of SrHA powders produced by both
methods displayed the presence of the following characteristic bands for hydroxyapatite:
3750 cm−1 (OH− stretch νOH); 1086 and 1022 cm
−1 (PO4
3− ν3); 962 cm
−1 (PO4
3− ν1);
630 cm−1 (OH− libration δOH); 600 and 570 cm
−1 (PO4
3− ν4). Additional band allocation
for the unsintered samples were as follows: broad peak centred around 3400 cm−1 (ab-
sorbed water molecules); 1455 and 1410 cm−1 (CO3
2− ν3); 880 cm
−1 (CO3
2− ν2). The band
at around 880 cm−1 may also be associated with hydrogen phosphate (P-OH ν2), but it is
generally accepted that the strong CO3
2− ν2 band obscures this activity [27]. The absorbed
water and carbonate groups (Figure 4A) were removed during high-temperature sintering
for the wet precipitation samples (Figure 4B). There was a clear shift in the position of
the phosphate group bands (1086, 1022 and 962 cm−1) to a lower wavenumber when an
increased amount of Sr was incorporated for both methods (Figure 5 and Figure S1 in
Supplementary Materials). For the wet precipitation method, shoulders on the phosphate
group bands were observed for the sintered samples (Figure 5B), which corresponded to
the presence of β-tricalcium phosphate (β-TCP) or β-tristrontium phosphate (β-TSP) [28];
the approximate positions were 990 cm−1 (for 0 at.% Sr), 974 cm−1 (for 2.5 and 5 at.% Sr)
and 1023 cm−1 (for 100 at. % Sr). The bands for the phosphate group activity for the 50 at.%
Sr nHA were not as clearly defined as the other Sr contents. This was observed for all the
samples analysed. The carbonate bands for the 50 and 100 at.% SrHA samples produced by
both methods were also less defined when compared to the other Sr contents (Figure 5C).
3.1.5. Radiopacity
The radiopacity of the SrHA powders increased with increasing Sr content (Figure 6A)
in a non-linear manner (Figure 6B). The radiopacity values recorded were slightly higher
for the powders produced using the sol-gel method (ranging from 3.4 to 7.7 mm of Al)
than those found for the powders produced using the wet precipitation method (ranging
from 2.0 to 6.6 mm of Al). However, the relationship between Sr at.% and radiopacity was
consistent between the samples produced using the two different methods.
3.2. In Vitro Biocompatibility
3.2.1. Direct Biocompatibility
Direct biocompatibility assays were affected by the disaggregation of pastes and
gels in culture. Specifically, the 5 at.% SrHA paste and the majority of the SrHA gel
samples disaggregated during culture. Excessive disaggregation contributed to a reduced
surface area of tissue culture plastic for cells to proliferate. Furthermore, the presence
of disaggregated paste and gel in the media may have disrupted the attached cells, as
fragments pass over cells whilst the plate was handled. Therefore, the assessment of
direct and indirect biocompatibility is appropriate in order to separately consider the
biocompatibility of the materials as well as any changes caused by the materials on tissue
culture media (i.e., changes in pH or the presence of elutes).
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Figure 4. FTIR-ATR spectra of SrHA powders (0, 50 and 100 at.% Sr) produced using the wet
precipitation method: unsintered (A) and sintered at 1000 ◦C (B).
Light microscopy and fluorescence microscopy showed the survival and morphology
of the cells in direct contact with the paste (Figures 7 and 8). For the fluorescence microscopy
images, some cells close to the paste had a rounded morphology, which may be due to
the growth of cells inside the pastes (Figure 8). The cells cultured alongside the SrHA
pastes did not have a significantly different viability to the cells cultured alone (Figure 9A).
However, the highest viability was observed in the cells cultured with 0 at.% SrHA paste,
and the lowest viability was observed with the paste containing 5 at.% SrHA.
The cells cultured with 0 and 100 at.% SrHA gels had significantly reduced viability
compared with the cells cultured on tissue culture plastic (Figure 9B). The cells cultured
with 50 at.% SrHA gel had the highest viability of the experimental gels tested in direct
culture. The SrHA gels were observed to disaggregate considerably during the 48 h
incubation period. Microscopy images displayed the growth of cells in direct contact with
gel fragments (Figure 7). Similarly to the live stain fluorescence images for the SrHA pastes,
cells with a rounded morphology were observed at the edges of the gels, which may have
been evidence of cells proliferating within the gels (Figure 8).
The comparison of the direct biocompatibility results for the SrHA pastes and gels
(Figure 9A,B) showed no consistent correlation between the amount of Sr in the materials
and the viability of cells cultured alongside them, with the highest direct viability results
for the pastes obtained with 0 at.% SrHA compared to 50 at.% SrHA for the gels.
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Figure 5. FTIR-ATR spectra of SrHA powders (0, 2.5, 5, 10, 50 and 100 at.% Sr) produced using the wet precipitation
method. Phosphate peaks of unsintered (A) and sintered (B) powders. Carbonate peaks of unsintered powders from wet
precipitation (C) and sol-gel (D) methods. Legend for all graphs as shown in A.
Figure 6. (A) Radiograph of SrHA powders (0, 2.5, 5, 10, 50 and 100 at.% Sr) produced using the wet
precipitation method, n = 3. Scale bar = 1 cm. (B) Radiopacity of SrHA powders (0, 2.5, 5, 10, 50 and
100 at.% Sr) produced using sol-gel and wet precipitation methods, n = 3.
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Figure 7. Light microscopy images for MG63 cells cultured directly with SrHA paste and gel (0 and 100 at.% Sr).
Scale bar = 200 µm.
 
Figure 8. Live fluorescence imaging for MG63 cells cultured directly with SrHA paste and gel (0 and 100 at.% Sr).
Scale bar = 200 µm.
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Figure 9. PrestoBlue® viability assay results for MG63 cells cultured directly for 48 h with SrHA (0, 2.5, 5, 10, 50 and 100 at.%
Sr) pastes (A) or gels (B) or indirectly for 24 h with SrHA pastes (C) or gels (D). ReproBone® novo used as control paste
alongside cells with no material present (n = 9). Error bars ± standard error of the mean. Significance level compared to
cells alone control * p < 0.05.
3.2.2. Indirect Biocompatibility
For the indirect assays, the 2.5, 5 and 10 at.% SrHA paste showed a significantly lower
viability than the cells cultured on tissue culture plastic (Figure 9C). Moreover, the 0 and
100 at.% SrHA pastes showed similar levels of viability as the cells cultured on tissue
culture plastic. A variable number of SrHA particles were observed in the pre-conditioned
media between the different materials tested, despite all media undergoing centrifugation
prior to application. Live/dead fluorescence images showed that the majority of cells were
alive, with few dead cells observed (Figure 10).
Pre-conditioned media, produced by incubation with the Sr gels, had no detrimental
effect on the viability of the cells (Figure 9D). Also, nHA particles were observed in the
gel pre-conditioned media after centrifugation, as observed for the paste pre-conditioned
media. Live/dead fluorescence images showed good cell survival, with few dead cells
observed (Figure 10).
Viability data for the indirect paste and gel cultures followed a similar pattern, with a
reduction in viability observed from 0 at.% to 5 at.% SrHA. The viability then increased for
the cells cultured indirectly with the 5 at.% to 100 at.% SrHA pastes and gels. The highest
levels of viability were observed for the 100 at.% SrHA paste and gel for the respective
ranges of materials.
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θ
Figure 10. Live/dead fluorescence imaging for MG63 cells cultured indirectly with SrHA paste and gel (0 and 100 at.% Sr).
Scale bar = 200 µm.
4. Discussion
The substitution of Sr for Ca in the HA crystal lattice had a variety of physicochemical
effects, which were detected using a comprehensive range of materials characterisation
techniques. Firstly, the increase in unit cell parameters for SrHA was evident in the peak
shift to lower degrees 2θ displayed in XRD patterns (Figure 1). This can be attributed to
the larger ionic radius of Sr (0.12 nm) when compared to Ca (0.099 nm), and causes a linear
unit cell increase over the whole range of Sr substitution (0–100 at.%) [17]. Sr is able to
substitute into both Ca sites within the HA crystal lattice, with some reports suggesting
a preference for Sr substitution into the M(II) site, particularly for Sr levels higher than
5 at.% [16,17,29]. The M(II) site has been described as ‘larger’ than M(I) to signify the
increased preference for the larger Sr ion to occupy this site. This is due to the ability of the
M(II) atoms to form staggered equilateral triangles, compared to the constrained columns
of the M(I) sites aligned parallel to the c-axis [16].
SrHA produced using the wet precipitation method displayed greater thermal insta-
bility with the co-presence of Sr and Ca in the crystal, with the lowest intensity breakdown
product peaks observed for 100 at.% Ca HA and 100 at.% SrHA (Figure 1B). This is likely
to be due to strain exerted on the crystal lattice, due to the larger ionic radius of Sr when
compared to Ca. This contributes to disorder within the crystals, with mixed Sr and Ca HA
products generally displaying smaller crystallite sizes [16,17]. This can be observed by the
broadening of the XRD peaks, with the unsintered 50 at.% SrHA samples produced using
both methods having the broadest peaks (Figure 1A,C). Further evidence for the reduced
crystallite size of the Sr and Ca mixed apatite was observed in the FTIR-ATR spectra
(Figures 4 and 5), where the phosphate group bands were broader for the 50 at.% SrHA
compared with all the other SrHA compositions produced using both methods. This effect
has also been correlated with a decreased product crystallite size and crystallinity [30,31].
The noticeable difference between the thermal stability of the SrHA produced by
the different methods (Figure 1) could not be attributed to Ca/Sr deficiency, as similar
(Ca + Sr)/P ratios (1.50 and 1.52) were obtained for the 100 at.% SrHA produced using the
wet precipitation and sol-gel methods, respectively (Tables 1 and 2). It has been reported
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that the presence of B-type carbonate substitution stabilises the apatite structure, due to
the presence of water in two types of vacancies [32]. The vacancies are present due to
the negative charge deficiency when the CO3
2− ion substitutes for the PO4
3− ion [33].
Therefore, B-type carbonate substitution may have contributed to the increased thermal
stability for the 100 at.% SrHA produced using the wet precipitation method. Although the
B-type carbonate substitution bands were less defined for 50 and 100 at.% SrHA produced
using both methods, it can be seen that the sol-gel samples showed a flatter profile in this
region (Figure 5D) than the wet precipitation materials (Figure 5C). Additionally, from
the TEM micrographs, it can be observed that the 100 at.% SrHA produced using the
sol-gel method (Figure 3) had much straighter edges and sharper vertices than the 100 at.%
SrHA produced using the wet precipitation method (Figure 2). This could suggest a higher
surface energy of the sol-gel 100 at.% SrHA, which in turn could contribute to its lower
thermal stability.
The TEM images clearly displayed the noticeable effect Sr had on the crystal growth
of the SrHA particles. Although much more pronounced for the sol-gel method (Figure 3),
it was still clear for the wet precipitation method that the 100 at.% SrHA was composed of
particles with a higher aspect ratio than the 100 at.% Ca nHA (Figure 2). This change in
particle aspect ratio suggested that the presence of Sr caused a change in the precipitation
rate. Specifically, growth along the c-axis may be promoted due to the energy required
for crystal growth being lower than the energy required for new crystal nucleation [34].
The mixed Ca–Sr nHA particles were generally composed of smaller sub particles with ill-
defined edges, particularly for the wet precipitation method. Similar effects were reported
elsewhere and corresponded with a lower degree of crystallinity [16].
The XRF results demonstrated that the level of incorporation of Sr was generally very
close to the attempted substitution level, albeit in a Ca/Sr deficient product (Tables 1 and 2).
This showed the readiness of Sr to substitute into the nHA crystal lattice, aided by the
isoelectric nature of the substitution of divalent Ca ions for divalent Sr ions.
The presence of Sr in the nHA had a clear effect on the phosphate group bands,
as shown by the peak shift to a lower wavenumber, observed in the FTIR-ATR spectra
(Figure 5). This has been attributed to the larger Sr atom altering the lattice vibrational
energies [16]. The FTIR-ATR spectra showed modest levels of carbonate substitution for
the SrHA produced using both methods (Figure 5C,D). The bands at around 1450 and
1420 cm−1 can be attributed to the B-type substitution of carbonate groups for phosphate
groups. A possible explanation for the carbonate substitution may be that the alkalinity
of the precipitation solutions allowed for dissolution of atmospheric carbon dioxide. The
carbonate groups observed for the wet precipitation method products were removed
during the sintering treatment at 1000 ◦C (Figure 4B).
The clear increase in radiopacity with increasing Sr content was expected, due to the
higher atomic mass of Sr compared to Ca (Figure 6). This allows Sr to absorb more X-ray
energy [35]. The density of the different powders may have contributed to the difference
seen between the powders produced by the different methods, as for the same Sr content, a
higher radiopacity was observed for the sol-gel powders. The difference in density may be
linked to the amount of absorbed water present in the powders.
The in vitro biocompatibility results highlighted the sensitivity of cultured cells to
different forms of SrHA-based materials, alongside the effects of different exposure routes.
Indeed, any differences in cellular viability observed in these experiments (Figure 9) may
have been due to a combination of effects arising from changes in HA chemistry, particle
morphology, culture configuration, or the water content of the SrHA pastes and gels.
Furthermore, disaggregation of the materials in tissue culture media is likely to have
contributed to some of the effects observed. In detail, SrHA gels consistently disaggregated
when submerged in tissue culture media, which may have allowed for more standardised
pre-conditioned media preparation for the indirect assays. In contrast, the 5 at.% SrHA
paste displayed the greatest disaggregation, thus increasing the surface area of exposure
during the preparation of the preconditioned media, and reducing the surface area in the
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well plate where cells could proliferate in an unconstrained manner for direct cultures.
These effects are likely to have contributed to the decreased viability of the cells cultured
directly and indirectly with this material. Therefore, the indirect biocompatibility results
(Figure 9C,D) may provide a more relevant insight than the direct biocompatibility results
(Figure 9A,B), due to the higher potential of the direct biocompatibility results being
dependent on these culture condition artefacts.
SrHA is known to have increased solubility compared to Ca nHA, with the increase in
solubility proportional to Sr content [13]. Therefore, it could be suggested that increased
solubility caused a higher concentration of dissolved ions, which may have affected cellular
viability through osmotic effects or other mechanisms. The presence of the larger Sr ion
has been proposed to contribute to the increased solubility of SrHA samples, due to a
destabilising effect on the crystal structure [13].
The difference between biocompatibility investigations observed for the pastes and
gels may have been affected by the different water contents of the two materials, since the
gel was composed of 90 wt.% water and the paste had an 80 wt.% water content. Therefore,
the SrHA paste cultures would have been subjected to a higher dose of nHA particles and
presumably a higher dose of any ions released from the materials. Conversely, the gel
materials had a greater potential to release more water into the media, which may have
affected the cellular response through osmotic effects.
For the various materials and culture configurations tested, there was no consistent
correlation between cellular viability and Sr content, suggesting that the increased amount
of Sr or changes in particle morphology were not detrimental to the viability of the cells
(Figure 9). With the exception of the cells cultured directly with the SrHA gels, the cellular
viability did not fall below 77%. This demonstrated the low cytotoxicity of the materials
tested, with a reduction in cellular viability to 70% or lower considered as cytotoxic in ISO
10993-5:2009 [26]. As mentioned above, the disaggregation of the gels in vitro was likely to
contribute to a reduction in viability, particularly for the direct gel assays.
Existing published reports on the biocompatibility of SrHA have concluded a variety
of optimal Sr concentrations. It must be noted that different Sr content ranges are often con-
sidered, which makes it difficult to compare between studies. Alongside this, investigations
of different forms of material and different particle morphologies can further complicate
the results, due to their distinct effects on cellular behaviour. Several experiments with
SrHA tested on MG63 cells have reported that the presence of Sr has a positive effect
on cellular viability [8,36] and early expression of alkaline phosphatase [37]. In contrast,
other investigations have found that SrHA has no significant effect on cellular viability
for MSCs [9] or for L929 fibroblasts [21]. These results highlight the limitations of in vitro
biocompatibility testing, as different results may be obtained using different cells types or
culture configurations. For instance, Crawford et al. have reported that nHA particles have
a cytotoxic effect for a range of cell types, with two-dimensional cultures showing increased
sensitivity compared to three-dimensional systems [38]. Therefore, it is necessary to test
promising compositions in vivo in order to fully realise the bone regeneration potential of
these materials in a representative defect model.
This work has demonstrated the successful production of SrHA pastes and gels using
relatively simple, rapid-mixing, low-cost methodologies. The current evidence suggests
that these materials are likely to have a beneficial biological response. In particular, the
detailed characterisation has provided evidence of SrHA being produced with bioinspired
features, including nanoscale dimensions, carbonate substitution, and Ca deficiency, all of
which may contribute to increased biological activity. Therefore, this study is of great value
in informing the development of the next generation of injectable nHA materials. Combined
with the findings of previous studies, this work demonstrates the potential to make further
inorganic modifications to generate multi-action biomaterials; for example the combination
of antibacterial properties with enhanced osteoconductivity to produce a biomaterial to
simultaneously combat bone infections and promote optimal bone tissue regeneration.
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5. Conclusions
Here, we present the first detailed study of the successful synthesis, characterisation
and side-by-side comparison of SrHA pastes and gels containing 0 to 100 at.% Sr, fabricated
using two different methodological approaches, rapid-mix wet precipitation and sol-gel.
Both methods produced a consistent and predictable incorporation of Sr into the final
product. In both cases, SrHA produced with 50 at.% Sr showed characteristics associated
with having the lowest crystallite size in the range of the materials produced. When SrHA
was fully substituted (i.e., 100 at.%), the particle aspect ratio was increased, most likely due
to altered precipitation kinetics. SrHA had greater radiopacity that was proportional to
its Sr content, which is a property with specific clinical benefits related to the detection of
material during deployment and monitoring post-surgery. In vitro biocompatibility tests
suggested that SrHA pastes and gels supported the growth of osteoblastic-like cells with
direct and indirect material contact, with comparable biocompatibility to a non-substituted
commercial bone graft substitute reference material. While the products from the two
methods were consistent, it was concluded that the rapid-mix wet precipitation was better
suited to translation to industry on account of its relative simplicity and proven versatility.
The Sr substitution accuracy using this method was also higher, with measured Sr levels
within +/− 0.5 at.% Sr across the whole range of substitutions attempted. The innovative
injectable materials reported here are potentially superior to current bone graft biomaterials
on account of assisting minimally invasive delivery and successful strontium incorporation,
which has the potential to impart greater radiopacity and improved stimulation of bone
tissue regeneration.
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